These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36159844)

  • 1. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
    Hasmim M; Xiao M; Van Moer K; Kumar A; Oniga A; Mittelbronn M; Duhem C; Chammout A; Berchem G; Thiery JP; Volpert M; Hollier B; Noman MZ; Janji B
    Front Immunol; 2022; 13():982821. PubMed ID: 36159844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells.
    Singh D; Deshmukh RK; Das A
    Cell Signal; 2021 Nov; 87():110151. PubMed ID: 34537302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
    Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
    Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
    Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
    Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
    Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
    Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
    Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
    Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for EMT in CD73 regulation in breast cancer.
    Hasmim M; Berchem G; Janji B
    Oncoimmunology; 2022; 11(1):2152636. PubMed ID: 36465484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
    Dong B; Ding Y; Huang Q; Guan X
    Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
    Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment.
    Gao B; Chen J; Han B; Zhang X; Hao J; Giuliano AE; Cui Y; Cui X
    Sci Rep; 2021 Jan; 11(1):2408. PubMed ID: 33510281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
    Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
    Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleraxis regulates Twist1 and Snai1 expression in the epithelial-to-mesenchymal transition.
    Al-Hattab DS; Safi HA; Nagalingam RS; Bagchi RA; Stecy MT; Czubryt MP
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H658-H668. PubMed ID: 29906225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.